Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The close medium term support offers good timing for purchasing the stock.
  • With a P/E ratio at 14 for the current year and 17.14 for next year, earnings multiples are highly attractive compared with competitors.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 1480 GBX
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
GLAXOSMITHKLINE PLC2.85%94 107
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720
ELI LILLY AND COMPANY22.09%186 883
NOVO NORDISK A/S4.18%168 128
AMGEN INC.10.26%147 580
BRISTOL-MYERS SQUIBB COMPAN..4.08%145 890
ASTRAZENECA PLC6.19%139 483
SANOFI3.51%124 582
JIANGSU HENGRUI MEDICINE CO..1.02%92 231
CHUGAI PHARMACEUTICAL CO., ..2.11%88 992
DAIICHI SANKYO COMPANY, LIM..1.27%66 704
More Results
Financials
Sales 2020 34 212 M 46 818 M 46 818 M
Net income 2020 4 888 M 6 690 M 6 690 M
Net Debt 2020 22 612 M 30 944 M 30 944 M
P/E ratio 2020 14,0x
Yield 2020 5,80%
Capitalization 68 876 M 94 107 M 94 255 M
EV / Sales 2020 2,67x
EV / Sales 2021 2,58x
Nbr of Employees 99 437
Free-Float 92,3%
Upcoming event on GLAXOSMITHKLINE PLC
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes